Macrocyclics is a research & development company actively engaged in the discovery and implementation of novel ligands and chelates for biomedical applications. Our technology platforms include high performance bifunctional ligands for diagnostic and therapeutic biotargeted radiopharmaceuticals and innovative magnetic resonance imaging agents that act as beacons for physiological processes. We are dedicated to providing a unique line of cost-effective products and services to help ensure the development and availability of effective pharmaceuticals to society. As part of this commitment we are proud to introduce in house cGMP production capabilities specifically designed to accelerate clinical development programs for our customers.

Our business philosophy is focused on the value of strong synergistic relationships. We participate in active partnerships with the biomedical community in academia as well as collaborations with pharmaceutical companies devoted to new product development. The recently announced research and development collaboration between Macrocyclics and MDS Nordion is representative of this strategy bringing together our expertise in chelation chemistry with the world leader in isotope production. We are excited about this new endeavor and the potential impact on the future of nuclear medicine.

Whether you are a researcher, an investor, a potential partner, or just interested in new biomedical products we hope that you find this site useful. Please give us your comments or suggestions here.